|
Published by: Datamonitor
Published: Jan. 7, 2003 - 249 Pages
Table of Contents
ABOUT DATAMONITOR HEALTHCARE
About the Immune Disorders and Inflammation pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
. Scope
. Datamonitor insight into the COPD market
. Key metrics
CHAPTER 2 Introduction and scope
CHAPTER 3 Patient potential
. Prevalence
Sources and methodology
Caveats and assumptions:
. Age and gender breakdown of COPD population,
Age
Gender
CHAPTER 4 Awareness
. Physician awareness
. Patient awareness
. Symptoms
CHAPTER 5 Diagnosis
. Diagnosis rates
. Physicians involved in patient presentation and diagnosis
Initial patient presentation physicians
Diagnosing physicians
. Diagnosis guidelines
. Diagnosis tests
Spirometry
Other tests
. Screening
. COPD vs asthma
. Types of COPD
. Co-morbidities of COPD
CHAPTER 6 Management of COPD
. Introduction
. Treatment guidelines
. Physicians managing COPD
Referrals
. Pharmacological vs non-pharmacological therapy
. Non-pharmacological therapy
Smoking cessation
. Pharmacological therapy
Drug classes prescribed
Beta2-agonists
Anticholinergics
Methylxanthines
Corticosteroids
Combination therapy
Expectorants
Other
Drug use by class
Breakdown of beta-agonist therapy
Breakdown of anticholinergic therapy
Breakdown of methylxanthine therapy
Breakdown of corticosteroid therapy
Breakdown of combination therapy
Breakdown of other therapy
Generic vs branded
. Drug delivery
. Compliance
Patient compliance with therapy
Deterrants to patient compliance
CHAPTER 7 Patient outcomes
. Desired outcomes
. COPD progression
. Hospitalizations
. Unmet needs
Novel therapies
Other future trends
CHAPTER 8 COPD treatment trees
. US
. Japan
. France
. Germany
. Italy
. Spain
. UK
CHAPTER 9 Interview transcripts
. Professor Peter Barnes
Awareness
Diagnosis
Drug treatment
Compliance
Unmet needs
. Professor Bruce Bochner
Awareness
Drug treatment
Compliance
Unmet needs
. Professor Roberto Rodriguez-Roisin
Awareness
Diagnosis
Drug treatment
Compliance
Unmet needs
. Professor William Henderson
Awareness
Diagnosis
Drug treatment
Compliance
Unmet needs
CHAPTER 10 Appendix
. Bibliography
. Physician research methodology
Hypothesis formulation
Opinion leader research
Pilot interviews
Physician recruitment
Hypothesis testing
Validation and quality control
Opinion leader research
Quality control
. Seven market drug treatment tables
US
Japan
France
Germany
Italy
Spain
UK
. Physician Sample breakdown
US
Japan
France
Germany
Italy
Spain
UK
. Table of tables
. List of figures
CHAPTER 11 APPENDIX B
. About Datamonitor
. Datamonitor Healthcare’s therapy area capabilities
DATASETS
Table 1: Prevalence and diagnosis rates of COPD in the seven major markets, 2002
Table 2: Breakdown of drug-treated population of COPD in the seven major markets, 2002
Table 3: Breakdown of the pharmacotherapy prescribed to diagnosed, drug-treated COPD patients, by disease severity, in the seven major markets, 2002
Table 4: Breakdown of the pharmacotherapy prescribed to all diagnosed, drug-treated, COPD patients in the seven major markets, 2002
Table 5: Prevalence of chronic COPD in the seven major markets, 2001
Table 6: Proportional male:female ratios of COPD in different age groups in the seven major markets, 2002
Table 7: Predicted physician awareness of COPD in the seven major markets, 2012
Table 8: Predicted patient awareness of COPD in the seven major markets, 2012
Table 9: Proportion of COPD patients suffering from symptoms in the seven major markets, 2002
Table 10: Proportion of monthly COPD patients which are newly diagnosed in the seven major markets, 2002 (%)
Table 11: Predicted diagnosis levels in the seven major markets, 2012
Table 12: Proportion of physicians involved in initial patient presentation in the seven major markets, 2002
Table 13: Proportion of physicians involved in patient diagnosis in the seven major markets, 2002
Table 14: Proportion of diagnostic guideline usage (%) in the seven major markets, 2002
Table 15: Tests used in the diagnosis of COPD in the seven major markets, 2002
Table 16: Average proportion of patients screened for COPD in the seven major markets, 2002
Table 17: Co-morbidities observed in COPD patients in the seven major markets, 2002
Table 18: Proportion of physicians involved in patient management in the seven major markets, 2002
Table 19: Proportion of PCP referral in the seven major markets, 2002
Table 20: Breakdown of patients treated with pharmacological only, non-pharmacological only and combination therapy, by disease severity, in the seven major markets, 2002
Table 21: Physician ranking of the three most important non-pharmacological therapies in the seven major markets, 2002
Tables 22 Breakdown of COPD patients prescribed pharmacological therapies to quit smoking in the seven major markets, 2002
Table 23-31: Proportion of diagnosed, drug-treated COPD patients, by disease severity, in the seven major markets, 2002, receiving the following therapies: inhaled beta2-agonists; oral beta2-agonists; anticholinergics; methylxanthines; inhaled corticosteroids; oral corticosteroids; other therapy
Table 32: Breakdown of COPD inhaled beta2-agonist treatment, by disease severity, in Europe, 2002
Table 33: Breakdown of COPD oral beta2-agonist treatment, by disease severity, in the seven major markets, 2002
Table 34: Breakdown of COPD anticholinergic treatment, by disease severity, in the seven major markets, 2002
Table 35: Breakdown of COPD methylxanthine treatment, by disease severity, in the seven major markets, 2002
Table 36: Breakdown of COPD inhaled corticosteroid treatment, by disease severity, in the seven major markets, 2002
Table 37: Breakdown of COPD oral corticosteroid treatment, by disease severity, in the seven major markets, 2002
Table 38: Breakdown of COPD combination therapy, by disease severity, in Europe, 2002
Table 39: Breakdown of COPD other treatments, by disease severity, in the seven major markets, 2002
Table 40: Proportion of generic vs branded COPD prescriptions according to drug category in the seven major markets, 2002
Table 41: Degree of patient compliance with COPD therapy, according to disease severity and drug category, in the seven major markets, 2002
Table 42: Measurements used to determine treatment efficacy in the seven major markets, 2002
Table 43: Time taken for COPD to develop in the seven major markets, 2002
Table 44: Survival time of severe COPD patients in the seven major markets, 2002
Table 45: Average physician ranking of unmet needs in COPD treatment in the seven major markets, 2002
Table 46-52: Breakdown of COPD treatment, in the US, by disease severity, 2002: inhaled beta2-agonists; oral beta2-agonists; anticholinergics; methylxanthines; inhaled corticosteroids; oral corticosteroids; combination therapy
Table 53-58: Breakdown of COPD treatment, in Japan, by disease severity, 2002: inhaled beta2-agonists; oral beta2-agonists; anticholinergics; methylxanthines; inhaled corticosteroids; oral corticosteroids
Table 59-65: Breakdown of COPD treatment, in France, by disease severity, 2002: inhaled beta2-agonists; oral beta2-agonists; anticholinergics; methylxanthines; inhaled corticosteroids; oral corticosteroids; combination therapy
Table 66-72: Breakdown of COPD treatment, in Germany, by disease severity, 2002: inhaled beta2-agonists; oral beta2-agonists; anticholinergics; methylxanthines; inhaled corticosteroids; oral corticosteroids; combination therapy
Table 73-79: Breakdown of COPD treatment, in Italy, by disease severity, 2002: inhaled beta2-agonists; oral beta2-agonists; anticholinergics; methylxanthines; inhaled corticosteroids; oral corticosteroids; combination therapy
Table 80-85: Breakdown of COPD treatment, in Spain, by disease severity, 2002: inhaled beta2-agonists; anticholinergics; methylxanthines; inhaled corticosteroids; oral corticosteroids; combination therapy
Table 86-92: Breakdown of COPD treatment, in the UK, by disease severity, 2002: inhaled beta2-agonists; oral beta2-agonists; anticholinergics; methylxanthines; inhaled corticosteroids; oral corticosteroids; combination therapy
Table 93-99: Physician sample breakdown: US; Japan; France; Germany; Italy; Spain; UK
AbstractIntroduction: Treatment Algorithms: Chronic Obstructive Pulmonary Disease (COPD) evaluates trends in the treatment of COPD in the US, Japan, France, Germany, Italy, Spain, and the UK. The analysis includes the overall use of drug classes, and specific drugs, based on interviews with 220 treating physicians. It enables companies to understand where their products fit in the current thinking of physicians, and evaluate future strategies that will best meet the unmet needs of the COPD population.Scope: * Key data and detailed analysis of the 7 leading country markets: the US, Japan, Germany, France, Italy, Spain, and the UK. * Analysis of the drugs classes used to treat COPD: beta2-agonists, anticholinergics, inhaled corticosteroids, combination therapies & methylxanthines. * Analysis of unmet needs and potentially successful strategies, based on physician response and opinion leader interviews. * Detailed treatment trees providing models of patients treated with specific classes and drugs, by disease severity. Report Highlights: COPD is under-diagnosed in all seven major markets, with diagnosis rates ranging from 25% in Japan to 59% in Italy, highlighting an untapped market of over 20 million patients for the manufacturers of first-line bronchodilators used to treat mild COPD. By supporting initiatives that encourage early diagnosis, Spiriva (tiotropium) will benefit more than Serevent (salmeterol) or Advair (salmeterol and fluticasone), due to its superior clinical profile.Approximately 60% of moderate and less than 50% of severe COPD patients reach the desired outcome of symptomatic relief, no further disease progression, and an improved overall quality of life. Poor success rates are a direct result of sub-optimal treatment strategies and continued smoking in up to half of severe patients. Drug companies must embrace extensive, sustained promotion of COPD if disease management and survival rates are to improve.Unmet need is extremely high in the treatment of COPD. Efficacy is of far greater concern than cost, providing a significant opportunity for premium price, pipeline products with novel mechanisms. Boehringer Ingelheim’s Spiriva, combination therapies, and potentially Altana/Pharmacia’s roflumilast, subject to favorable Phase III trial results, are likely to form the cornerstone of future treatment strategies. Reasons to Purchase: * Understand treatment trends across seven markets, by disease severity, to evaluate potential for current and pipeline products. * Assess the role of inhaled corticosteroids in the treatment of COPD, and the impact of Spiriva (tiotropium) on future treatment regimens.* Evaluate markets where the patient population, or the use of a drug class in particular, is underpenetrated, to best position your products. * Identify the leading products in each market, to build an understanding of the factors that contribute to success on the COPD market in each country.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
